News | Artificial Intelligence | February 23, 2024

Cleerly ISCHEMIA Software Device Billable With AMA Category I CPT Code for Noninvasive Estimates of Fractional Flow Reserve

FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease

FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease

February 23, 2024 — Cleerly, the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Food and Drug Administration (FDA)-cleared Cleerly ISCHEMIA software device applied to a non-invasive coronary CT angiogram (CCTA) can be billed using the new Category I CPT code 75580. The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making. The Category I CPT code is an addition to the Category III CPT codes (CPT 0623T, 0624T, 0625T, 0626T) used for reporting Cleerly’s advanced coronary atherosclerosis analysis.

Effective January 1, 2024, the AMA published updates to its CPT code set to include a new Category I CPT code 75580, described as, "Noninvasive estimate of coronary fractional flow reserve derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified healthcare professional."  The Cleerly ISCHEMIA software outputs an index with its "threshold equivalent to invasive FFR >0.80 vs. ≤0.80 as identified in professional societal practice guidelines." 1

The Cleerly ISCHEMIA software outputs data that is augmentative to support clinical decision making by both the interpreting imaging physician as well as the treating physician. This analysis enables the imaging and treating physicians to interrogate each lesion across all coronary vessels in order to perform lesion-by-lesion mapping of actionable anatomic and physiologic findings of coronary artery disease in order to offer greater understanding of the pathology, and encourage the development of a personalized treatment management plan for the patient.

"The Cleerly ISCHEMIA software provides noninvasive estimates of FFR values that help healthcare professionals make critical decisions in the management of patients with suspected coronary artery disease," said James P. Earls, MD, Chief Medical Officer of Cleerly. "Cleerly ISCHEMIA was purposely designed to output estimates of FFR values that are guideline-recommended by professional societies, and to allow comprehensive mapping of both anatomic and physiologic data for each and every coronary lesion across the entire vascular tree."

Prior studies have demonstrated the independent and incremental benefit of Cleerly ISCHEMIA applied to CCTA beyond traditional assessment. The application of Cleerly ISCHEMIA supports improvements in physician certainty, guides medical therapy decision making, and reduces unnecessary invasive and non-invasive testing.2-6

For more information: www.cleerlyhealth.com

References:

  1. FDA 510(k) Number K231335 Summary for Cleerly ISCHEMIA.
  2. Nurmohamed NS, Danad I, Jukema R. High Diagnostic Accuracy Of AI-Ischemia in Comparison To PET, FFR-CT, SPECT, and Invasive FFR: A PACIFIC Sub-Study. Sponsored by Cleerly and Presented at the American College of Cardiology Annual Scientific Meeting New Orleans LA 2023.
  3. van Rosendael A, Danad I, CREDENCE study group, PACIFIC study group. Derivation, Validation and Prognostic Assessment of an AI-Based Algorithm for Determination of Coronary Ischemia: The CREDENCE and PACIFIC Trial. in European Association of Cardiovascular Imaging: Late Breaking Clinical Research and Trials. 2023. Barcelona, Spain.
  4. Chiou A, Hermel M, Miller G et al. Cleerly® Vs. Heartflow® vs. Site Read in The Per-Vessel Prediction of Adenosine FFR ≤0.80 With Plaque Features Associated with False Positives. Presented at the American College of Cardiology Annual Scientific Meeting New Orleans LA 2023
  5. Karlsberg RP, Gonzalez Quesada C, Samuels B et al. High diagnostic accuracy of a novel artificial intelligence guided quantitative coronary computed tomography algorithm for predicting myocardial ischemia. Presented at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting Boston MA 2023. Journal of Cardiovascular Computed Tomography Vol. 17 Issue 4 Supplement S28–S29 Published in issue: July, 2023.
  6. Bär S, Nabeta T, Maaniitty T. Prognostic Value of a Novel Artificial Intelligence-Based Coronary Computed Tomography Angiography-Derived Ischemia Algorithm for Patients with Suspected Coronary Artery Disease. Eur Heart J Cardiovasc Imaging. 2023 Dec 12:jead339. Epub ahead of print. PMID: 38084894.

Related Content

News | Artificial Intelligence

May 2, 2024 — Artificial intelligence experts at Cedars-Sinai and the Smidt Heart Institute created a dataset with more ...

Home May 02, 2024
Home
News | Artificial Intelligence

May 1, 2024 — In an ischemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer ...

Home May 01, 2024
Home
News | Artificial Intelligence

April 24, 2024 — Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence (AI)-powered medical ...

Home April 24, 2024
Home
News | Artificial Intelligence

April 23, 2024 — A recent study designed and implemented by investigators at Cedars-Sinai found that artificial ...

Home April 23, 2024
Home
News | Artificial Intelligence

April 18, 2024 — Karoo Health, the only operational provider of cardiac value-based care (VBC) enablement with published ...

Home April 18, 2024
Home
News | Artificial Intelligence

April 6, 2024 — Experts from the Smidt Heart Institute at Cedars-Sinai will share new research and participate in more ...

Home April 06, 2024
Home
News | Artificial Intelligence

March 28, 2024 — Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart ...

Home March 28, 2024
Home
News | Artificial Intelligence

March 27 2024 — HeartFlow, Inc., a leader in AI-driven healthcare technology, announced the launch of the DECIDE ...

Home March 27, 2024
Home
News | Artificial Intelligence

March 7, 2024 — GE HealthCare will showcase its industry-leading portfolio of artificial intelligence (AI)-enabled ...

Home March 07, 2024
Home
Subscribe Now